|Table of Contents|

Clinical efficacy of thalidomide combined with temozolomide and radiation therapy in the treatment of residual lesions after high-grade glioma surgery

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2020 02
Page:
219-223
Research Field:
Publishing date:

Info

Title:
Clinical efficacy of thalidomide combined with temozolomide and radiation therapy in the treatment of residual lesions after high-grade glioma surgery
Author(s):
Xu Liben; Wu Chaoyang; Wang Yuandong; Wang Yan
Department of Radiotherapy,the Affiliated People's Hospital of Jiangsu University,Jiangsu Zhenjiang 212000,China.
Keywords:
thalidomide; high-grade glioma; efficacy; safety
PACS:
R730.264
DOI:
10.3969/j.issn.1672-4992.2020.02.009
Abstract:
Objective:To explore the clinical efficacy and safety of thalidomide combined with temozolomide and intensity modulated radiation (IMRT) in the treatment of residual lesions after high-grade glioma surgery.Methods:A retrospective analysis was made on 60 patients with residual lesions after high-grade glioma surgery in our hospital,30 in each group respectively.The control group was intensity modulated radiotherapy and mozolomide,while the observation group was intensity modulated radiotherapy plus temozolomide and thalidomide.The clinical effective rate,disease control rate,adverse reactions and safety,1 year and 2 years PFS/OS of two groups were analyzed.Results:There were 3 cases of complete response (CR),10 cases of partial response (PR),12 cases of stable disease (SD),5 cases of progression of disease (PD) in the control group.There were 6 cases of complete response (CR),15 cases of partial response (PR),8 cases of stable disease (SD),1 case of progression of disease (PD) in the observation group.RR was 43.33% in the control group,70.00% in the observation group (P=0.037).DCR was 83.33% in the control group,96.67% in the observation group (P=0.085).The main adverse reactions included I-II degree myelosuppression and abnormal liver function (P＞0.05).The incidence of nausea and vomiting in control group and observation group were 56.67% and 26.67% (P=0.018).The incidence of sleepiness and constipation in the observation group was 16.67% and 36.67%,while that in the control group was 0 and 13.33% (P=0.02/P=0.037).The improvement rate of KPS score in observation group and control group was 60.00%,33.33%,and the decrease rate of KPS score was 10.00% and 30.00% (P=0.038/P=0.028).The OS of control group and observation group was 43.3%,16.3%,73.3% and 33.7% in 1 and 2 years,and the median OS was 12 months and 15 months (P=0.046).The PFS was 31%,3.9% and 48.9%,7.8% in 1 and 2 years.The median PFS was 8 months and 12 months (P=0.025).Conclusion:Thalidomide combined with temozolomide intensity modulated radiation therapy is superior to the control group in the treatment of residual lesions after high-grade glioma surgery.It is safe,effective,tolerable and worthy of further study.

References:

［1］Zhou X,Liao X,Zhang B,et al.Recurrence patterns in patients with high-grade glioma following temozolomide-based chemoradiotherapy［J］.Mol Clin Oncol,2016,5(2):289-294.
［2］FAN QR,WANG ER,ZHANG L.Analysis of surgical treatment effect and recurrence influencing factors in 75 patients with glioma［J］.Laboratory Medicine and Clinical Practice,2017,14(17):2544-2546.［樊庆荣,王恩任,张列.75例脑胶质瘤患者手术治疗效果及复发影响因素分析［J］.检验医学与临床,2017,14(17):2544-2546.］
［3］Alexander BM,Wang M,Yung WK,et al.A phase Ⅱ study of conventional radiation therapy and thalidomide for supratentorial,newly-diagnosed glioblastoma(RTOG9806)［J］.J Neurooncol,2013,111(1):33-39.
［4］Ciammella P,Galeandro MD，Abbiero N,et al.Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme:A 6 years single institutional experience［J］.Clin Neurol Neurosurg,2013,115(9):1609-1614.
［5］Wolff JE,Berrak S,Koontz W,et al.Nitrosourea efficacy in hjgh-grade glioma:A survival gain analysis summarizing 504 eohoas with 24 193 patients［J］.JN Euro Oncol,2008(88):57-63．
［6］Brastianos PK,Batchelor TT.Vascular endothelial growth factor in hibitors in malignant gliomas［J］.Target Oncnl,2010,5(3):167-174．
［7］Yasuda H,Ando J,Sato E,et al.Unccessful treatment of extramedullary tumors with low-dose thalidomide in patients with multiple myeloma［J］.Intern Med,2010,49(23):2617-2620.
［8］LEI L,WANG X,WANG XJ.Research progress of thalidomide in the treatment of common non-hematologic tumors［J］.Int Oncol,2016,43(9):711-714.［雷蕾,王娴,王晓稼.沙利度胺治疗常见非血液系统肿瘤的研究进展［J］.国际肿瘤学杂志,2016,43(9):711-714.］
［9］YANG JG,CHEN JZ,ZHAO CJ,et al.Application and research progress of thalidomide in the treatment of advanced solid tumors［J］.Modern Oncology,2017,25(11):1805-1809.［杨建刚,陈继正,赵参军,等.沙利度胺在治疗晚期实体肿瘤中的应用及研究进展［J］.现代肿瘤医学,2017,25(11):1805-1809.］
［10］Ock CY,Oh DY,Lee J,et al.Weight loss at the first month of palliative chemotherapy predicts survival outcomes in patients with advanced gastric cancer［J］.Gastric Cancer,2016,19(2):597-606.
［11］XU J,ZHOU WB,LI HP.Thalidomide improve quality of life in patients with malignant tumor chemotherapy research and analysis［J］.Chinese Journal of Cancer Prevention and Treatment,2018,25(S1):177-179.［徐洁,周文彪,李袆萍.沙利度胺改善恶性肿瘤化疗患者生活质量研究分析［J］.中华肿瘤防治杂志,2018,25(S1):177-179.］
［12］Porkholm M,Valanne L,Lonnqvist T,et al.Radiationtherapy and concurrent topotecan followed by maintenance triple anti-angiogenic therapy with thalidomide,etoposide,and celecoxib for pediatric diffuse intrinsic pontine glioma［J］.Pediatr Blood Cancer,2014,61(9):1603-1609.
［13］Stupp R,Mason WP,Van Dent MJ,et al.Radiotherapy plus concomitant and adjuvant temozolomide for glioblas-toma［J］.N Engl J Med,2005,352(10):987-996.
［14］Stupp R,Hegi ME,Mason WP,et al.National Cancer Institute of Canada Clinical Trials.Effects of radiotherapy with concomitant and adjuvant temozolomide versus radio-therapyalone on survival in glioblastoma in a randomised phase Ⅲ study:5-year analysis of the EORTC-NCIC trial［J］.Lancet Oncol,2009,10(5):459-466.
［15］FENG G,CHEN HM.Clinical effect of thalidomide on cisplatin-induced delayed vomiting［J］.Chinese Journal of Clinical Research,2015,28(10):1329-1330.［封革,陈慧敏.沙利度胺对顺铂所致迟发性呕吐的临床疗效观察［J］.中国临床研究,2015,28(10):1329-1330.］
［16］ZHAO W,YU PY.Clinical observation of thalidomide in the treatment of delayed vomiting after chemotherapy［J］.Chinese Journal of Convalescent Medicine,2016,25(2):201-202.［赵微,于佩瑶.沙利度胺治疗化疗迟发性呕吐的临床观察［J］.中国疗养医学,2016,25(2):201-202.］
［17］Yuan L,Wu GH.ATP ubiquitin-proteasome pathway in cancer research progress in the role of evil fluid to pledge amyotrophy［J］.Chin Clinical Medicine,2008,15(6):914-916.
［18］Mantovani G,Maccio A,Madeddu C,et al.Clinical trial with thalidomide in patients with tumors at different sites in progression of disease after previous treatments［J］.Support Palliat Cancer Care,2004,1(2):21-28.

Memo

Memo:
2018年度镇江市社会发展指导性项目（编号：FZ2018034）;江苏大学2018年度临床医学科技发展基金（编号：JLY20180001）
Last Update: 2019-11-29